Asiri Laboratories earns 15189-2012 accreditation

Tuesday, 12 May 2015 00:46 -     - {{hitsCtrl.values.hits}}

The first and only laboratory to achieve this gold standard in Sri Lanka, it sets them apart from the rest locally and places them amongst global leaders in pathology services while adding to a legacy of patient and medical profession trust


Asiri Laboratory, a market leader in diagnostics, recently received the prestigious 15189-2012 international accreditation, confirming its reputation for competence and effectiveness in the modernisation and development of pathology and laboratory services among lab customers and the medical profession. Asiri Laboratory is the first organisation in Sri Lanka to obtain this new version.

The globally recognised standard, evolved from its predecessor 15189-2007, evaluates excellence at every touch point of medical lab services, starting with advice to clinicians, collection, transport and reception, examination of finished samples plus reporting and interpretation. The tough audit and stringent accreditation assures performance, encompassing products, people, facilities and supply chains through verification, assessment, training and services to create superior stakeholder and customer trust.

“I wish to extend my personal thanks and congratulations to the staff of Asiri Laboratory,” said Asiri Laboratories Director Neil Priyath John.

“In all ways, this accreditation endorses the fact that our lab and facilities are making tremendous strides in providing the highest quality of care to our customers.


“The affirmation by an independent reviewer strengthens our determination to excel at all levels of delivery,” he went on to note, while adding that it was important to choose the right clinical lab to get accurate results since treatment was based on the results.

Medical experts confirm that accuracy of results is paramount to treatment therefore accreditation becomes a vital compliance. Asiri Laboratory will benefit from this industry-wide recognition in that the latest best practice modules are in place, which underscores performance and enters them into a highly respected network of similar labs across the world for cross border treatments.  

The 30-year-old industry leader recently added a host of new pathology tests to its already large portfolio, some of which are Immature Platelet Fraction (IPF) to predict platelet recovery in dengue patients, H-Pylori diagnosis and Vitamin D serum tests.

The Asiri Group of Hospitals, owned by the Softlogic Group, comprises Asiri Laboratory, Asiri Surgical Hospital Plc, Asiri Hospital Holdings Plc, The Central Hospital and Asiri Hospital Matara Ltd. The group, which has won several awards in healthcare and related services over the years, is dedicated to offering technologically-driven and cutting-edge healthcare service.